Medera presents updated results from gene therapy trial for heart failure
Medera announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy ...
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...
AHA/ASA Journals20h
Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...
Physician's Weekly22h
Triglyceride-Glucose Index and Long-Term Heart Failure Risk
The following is a summary of "Association of triglyceride-glucose index trajectories with the risk of worsening heart ...